Response Genetics Stock Price, News & Analysis (OTCMKTS:RGDXQ)

$0.0005 +0.00 (+25.00 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$0.00
Today's Range$0.00 - $0.00
52-Week Range$0.00 - $0.00
Volume2.04 million shs
Average Volume171,914 shs
Market Capitalization$20,000.00
P/E RatioN/A
Dividend YieldN/A

About Response Genetics (OTCMKTS:RGDXQ)

Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Receive RGDXQ News and Ratings via Email

Sign-up to receive the latest news and ratings for RGDXQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Laboratories & Research


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares38,790,000

Response Genetics (OTCMKTS:RGDXQ) Frequently Asked Questions

What is Response Genetics' stock symbol?

Response Genetics trades on the OTCMKTS under the ticker symbol "RGDXQ."

How were Response Genetics' earnings last quarter?

Response Genetics, Inc. (OTCMKTS:RGDXQ) issued its quarterly earnings results on Tuesday, March, 31st. The medical research company reported ($0.09) EPS for the quarter. The medical research company had revenue of $4.10 million for the quarter. View Response Genetics' Earnings History.

Who are some of Response Genetics' key competitors?

Who are Response Genetics' key executives?

Response Genetics' management team includes the folowing people:

  • Thomas A. Bologna, Chairman of the Board, Chief Executive Officer (Age 66)
  • Kevin Roy Harris, Chief Financial Officer, Vice President (Age 47)
  • Adanech Getachew, General Counsel (Age 37)
  • Kirk K. Calhoun, Lead Independent Director (Age 73)
  • Michael Serruya, Director (Age 51)
  • Sam Chawla, Independent Director (Age 41)
  • David R Schreiber, Independent Director (Age 55)
  • Richard A. van den Broek, Independent Director (Age 49)

How do I buy Response Genetics stock?

Shares of Response Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Response Genetics' stock price today?

One share of Response Genetics stock can currently be purchased for approximately $0.00.

How big of a company is Response Genetics?

Response Genetics has a market capitalization of $20,000.00.

How can I contact Response Genetics?

Response Genetics' mailing address is 1640 MARENGO ST 7TH FLOOR, LOS ANGELES CA, 90033. The medical research company can be reached via phone at 323-224-3900 or via email at [email protected]

MarketBeat Community Rating for Response Genetics (RGDXQ)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Response Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Response Genetics (OTCMKTS:RGDXQ) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Response Genetics (OTCMKTS:RGDXQ) Earnings History and Estimates Chart

Earnings by Quarter for Response Genetics (OTCMKTS:RGDXQ)

Response Genetics (OTCMKTS RGDXQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2015Q115($0.10)$3.90 million$3.80 millionViewListenView Earnings Details
3/31/2015Q414($0.09)$4.10 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)$4.47 millionViewN/AView Earnings Details
8/14/2014Q214($0.08)$3.90 million$4.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.06)($0.03)$5.50 million$3.90 millionViewN/AView Earnings Details
3/20/2014Q413($0.07)($0.09)$5.30 million$4.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.07)($0.08)$5.40 million$4.10 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.04)($0.11)$5.40 million$5.30 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.04)($0.03)$4.92 million$5.60 millionViewN/AView Earnings Details
3/21/2013Q4 2012($0.06)($0.01)ViewN/AView Earnings Details
11/13/2012Q312($0.07)($0.05)$4.50 million$5.40 millionViewN/AView Earnings Details
8/14/2012Q2 2012($0.12)($0.11)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.10)($0.14)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.04)($0.20)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.02)($0.07)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.07)($0.01)ViewN/AView Earnings Details
3/29/2011Q4 2010($0.08)($0.06)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.11)($0.06)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.11)($0.11)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.12)($0.13)ViewN/AView Earnings Details
3/31/2010Q4 2009($0.11)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.15)($0.14)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.27)($0.19)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.30)ViewN/AView Earnings Details
3/26/2009Q4 2008($0.24)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.19)($0.21)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.17)($0.58)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.17)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Response Genetics (OTCMKTS:RGDXQ) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Response Genetics (OTCMKTS:RGDXQ)

No dividend announcements for this company have been tracked by

Insider Trades

Response Genetics (OTCMKTS RGDXQ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.85%
Insider Trades by Quarter for Response Genetics (OTCMKTS:RGDXQ)

Response Genetics (OTCMKTS RGDXQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell134,991$1.11$149,840.01View SEC Filing  
12/19/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell135,666$1.18$160,085.88View SEC Filing  
12/16/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell353,677$1.17$413,802.09View SEC Filing  
11/27/2012Austin W & Greenhouse Da MarxeMajor ShareholderBuy463,278$1.02$472,543.56View SEC Filing  
(Data available from 1/1/2013 forward)


Response Genetics (OTCMKTS RGDXQ) News Headlines


SEC Filings

Response Genetics (OTCMKTS:RGDXQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Response Genetics (OTCMKTS RGDXQ) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.